While the benefits of gastric bypass (GB) surgery in type 2 diabetes are well established, few studies have evaluated the long-term effects of GB in patients with type 1 diabetes (1, 2) , and these studies demonstrate conflicting effects on glycemic control. This is clinically important given the increasing prevalence of obesity in patients with type 1 diabetes (3). We studied 10 severely obese women with confirmed type 1 diabetes, as previously described (4), and evaluated outcomes prior to GB and at 1 and 5 years following surgery. Mean age at GB was 39.6 6 8.4 years, mean duration of type 1 diabetes 24.6 6 10.1 years, and mean age at diagnosis 16.0 6 8.3 years. Six subjects used continuous subcutaneous insulin infusion.
BMI decreased by 33% from baseline at 1 year postoperatively (from 43.5 6 7.5 to 29.3 6 5.4 kg/m 2 , P , 0.0001) but increased by a mean of 15% (to 33.8 6 7.5 kg/m 2 , P , 0.01) from 1 to 5 years (Table 1) . Compared with baseline, HbA 1c was unchanged at 1 year (baseline 8.1 6 1.3% [65 6 14.2 mmol/mol] to 1 year 8.3 6 1.4% [67 6 15.3 mmol/mol], P 5 0.47). Interestingly, HbA 1c trended upward at 5 years postoperatively to 9.8 6 1.9% (84 6 20.8 mmol/mol, P 5 0.15). Basal insulin requirements decreased from 53.0 6 29.7 to 23.0 6 15.6 units/day (P 5 0.0005) at 1 year postoperatively but trended up from 1 to 5 years to 31.1 6 22.8 units/day (P 5 0.17). The trend held even when accounting for body weight. There was a robust correlation between change in insulin dose and weight (r 5 0.66; P 5 0.04).
Cardiometabolic risk factor assessment showed decreases in plasma triglycerides (28% decrease, P 5 0.004) and systolic blood pressure (mean decrease of 11 6 8.3 mmHg, P 5 0.003) at 1 year; however, these decreases were not sustained at 5 years. There was no significant change in diastolic blood pressure, total cholesterol, or LDL. Interestingly, HDL increased by 22% from 1 to 5 years following GB surgery (P 5 0.004). Despite limited data on diabetes-related complications, microalbuminuria tended to improve, though this was largely driven by one subject. One subject had severe nonproliferative diabetic retinopathy (NPDR) at baseline, which improved to moderate NPDR at 1-year follow-up; moderate NPDR was unchanged in two subjects 1 year postoperatively.
We conclude that GB does not improve long-term glycemic control in severely obese women with type 1 diabetes. However, GB reduced body weight and improved several cardiometabolic risk factors for up to 5 years following surgery. The lack of sustained effect of GB on glycemic control in individuals with type 1 diabetes is likely a consequence of their persistent absolute insulin requirement, resulting in periods of fasting hyperglycemia and increased variability of postprandial glucose excursions, as previously demonstrated in subjects with type 2 diabetes after GB (5). GB markedly alters patterns of early postprandial glycemia, contributing to a potential mismatch between nutrient absorption and prandial insulin timing.
Our study was limited by small sample size and single-sex cohort. Nevertheless, our evaluation of anthropometric, glycemic, and cardiometabolic outcomes at multiple time points following GB surgery in severely obese women with type 1 diabetes suggests that GB induces weight loss and improvement of some cardiovascular risk factors but does not improve long-term glycemic control in women with type 1 diabetes. Table 1 -Anthropometric and cardiometabolic risk factors and glycemic control at baseline (n 5 10) and at 1 (n 5 10) and 5 (n 5 7) years following GB surgery Data are presented as mean 6 SD, unless otherwise noted. †1 year compared with baseline. ‡5 years compared with baseline. §5 years compared with 1 year. *Significant at P , 0.05. **Significant at P , 0.001.
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